US · Healthcare · Medical Instruments & Supplies
EPS came in at 2.91 against a street estimate of 2.67 — a beat of 9.0%.
Analysts rate ResMed Inc a buy (9 buy, 10 hold, 1 sell out of 20) with an average price target of $265.11.
CONFIDENT ResMed delivered strong Q1 growth, margin expansion and EPS upside, while maintaining FY27 guidance despite Astral headwinds, inflation and planned investment. Q1 FY27 Rest-of-World growth benefited partly from a France fleet refresh expected to pressure the second half. Analysts pressed on margin upside, regional demand, marketing timing, GLP-1 effects, competition, portfolio opportunities and U.S. manufacturing. Management emphasized productivity, disciplined guidance, continued demand and long-term ecosystem growth. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.76% |
| Vanguard Capital Management, LLC | 6.74% |
| Vanguard Portfolio Management, LLC | 5.63% |
| State Street Corp | 4.75% |
| Geode Capital Management, LLC | 3.09% |
| Bank of New York Mellon Corp | 2.98% |
| First Trust Advisors L.P. | 1.62% |
| Amvescap Plc. | 1.47% |
| Document | Date |
|---|---|
| Quarterly report · Q1 FY2027 HEADLINE NUMBERS • Q1 fiscal 2027 net revenue was $1,414,814, up from $1,335,582 in the prior-year quarter. • Net income was $418,413, compared with | 2026-10-30 |
| Results announced · Q2 FY2027 HEADLINE NUMBERS • Q1 fiscal 2027 revenue increased 6% to $1,414,814 thousand, or approximately $1.4 billion; core constant-currency revenue increase | 2026-10-29 |
| Proxy statement · Q4 FY2026 EXECUTIVE PAY • CEO Michael “Mick” Farrell’s total compensation for fiscal year 2026 was not included in the provided excerpt, so the exact amount an | 2026-10-01 |
| Company announcement · Q1 FY2027 RESMED INC. – 8-K SUMMARY (August 31, 2026) HEADLINE NUMBERS • Company entered accelerated share repurchase (ASR) agreement on August 31, 2026 • Tot | 2026-09-01 |
| Board / officer change · Q1 FY2027 RESMED INC. (RMD) - 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 17, 2026 (Event Date: August 13, 2026) • Company: ResMed Inc., Delawar | 2026-08-17 |
| Annual report FY2026 RESMED INC. — FORM 10-K FISCAL YEAR ENDED JUNE 30, 2026 HEADLINE NUMBERS • Market capitalization: $34.9 billion (as of December 31, 2025) • Shares o | 2026-08-13 |
| Results announced · Q1 FY2027 RESMED INC. — Q4 FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY2026 revenue: $1.5 billion, up 9% reported (8% constant currency) • Full-year FY202 | 2026-08-06 |
| Results announced · Q4 FY2026 RESMED INC. - 8-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • MatrixCare business sale price: $490 million all-cash transaction • MatrixCare ann | 2026-07-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.66 / share ex-date Nov 12, 2026 · pay Dec 17, 2026 | 2026-11-12 |
| Dividend | $0.66 / share ex-date Aug 20, 2026 · pay Sep 24, 2026 | 2026-08-20 |
| Dividend | $0.60 / share ex-date May 14, 2026 · pay Jun 18, 2026 | 2026-05-14 |
| Dividend | $0.60 / share ex-date Feb 12, 2026 · pay Mar 16, 2026 | 2026-02-12 |
| Dividend | $0.60 / share ex-date Nov 13, 2025 · pay Dec 18, 2025 | 2025-11-13 |
| Announcement | Date |
|---|---|
| Quarterly cash dividend of $0.66 per share declared ResMed’s board declared a quarterly cash dividend of $0.66 per NYSE common share. The record date is November 12, 2026, and the dividend will be paid on December 17, 2026. The shares will tr | 2026-10-29 |
| Accelerated share repurchase agreement for $450 million announced ResMed announced on August 31, 2026 that it entered into an accelerated share repurchase (ASR) agreement with Citibank to buy back $450 million of its own stock. Here's what this means: WHA | 2026-09-01 |
| Quarterly cash dividend increased 10% to $0.66 per share ResMed's board of directors announced on August 6, 2026, a quarterly cash dividend increase to $0.66 per share, up 10% from the previous quarterly dividend. The dividend will be paid on Sept | 2026-08-06 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ResMed Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.